Paper Details

  1. Home
  2. Paper Details

Midazolam versus fentanyl/droperidol and placebo as intramuscular premedicant.

Author: StijnenT, de Voogt-FrenkelE, van WijheM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Midazolam was more effective than fentanyl/droperidol and placebo in reducing anxiety levels in 203 patients. It also caused more confusion and somnolence than placebo but less than fentanyl/droperidol.
Paper Details　
Original Abstract of the Article :
Midazolam, a new short-acting benzodiazepine with promising premedicant effects, was investigated in a double-blind, randomized clinical trial in 203 patients versus fentanyl/droperidol and placebo. Subjective effects, side-effects, amnesia and overall satisfaction were recorded. Midazolam caused th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1399-6576.1985.tb02225.x

データ提供：米国国立医学図書館（NLM）

Midazolam as a Pre-Operative Anxiolytic

The world of pre-operative anxiety is a challenging one. Imagine a patient awaiting a procedure, their mind racing with a whirlwind of emotions. This study sought to find an effective and safe solution for reducing anxiety before surgery by comparing the effects of midazolam, fentanyl/droperidol, and placebo. The authors used a double-blind, randomized clinical trial involving 203 patients. This meticulous approach allowed for a thorough comparison of these pre-medications. The study found that midazolam effectively reduced anxiety levels compared to placebo and fentanyl/droperidol.

Midazolam: A Balancing Act

While midazolam did cause more confusion and somnolence than placebo, it was less likely to cause these side effects than fentanyl/droperidol. Midazolam also led to anterograde amnesia in about half of the patients. This means that these individuals could not remember events that occurred after taking the medication, which may be a desirable outcome in certain situations. The study also found that patients who received midazolam reported higher satisfaction levels compared to the other groups.

Navigating the Side Effects

The study found that midazolam was a promising pre-operative anxiolytic, but it is essential to consider the potential side effects. The authors emphasize that the drug should be used with caution, especially in patients with pre-existing conditions or who are particularly susceptible to the effects of sedation. The study's findings are a valuable addition to the growing body of knowledge about pre-operative medications. It provides clinicians with important information for choosing the most appropriate treatment for their patients.

Dr. Camel's Conclusion

This study, like a shimmering mirage in the desert, offers a glimpse of a potential solution for pre-operative anxiety. Midazolam emerges as a promising anxiolytic, but like a desert oasis, it must be approached with careful consideration of its side effects and potential risks. The authors' meticulous research provides valuable insights that will help clinicians make informed decisions about the best course of treatment for their patients.

Date :
  1. Date Completed 1985-08-21
  2. Date Revised 2019-08-14
Further Info :

Pubmed ID

3160209

DOI: Digital Object Identifier

10.1111/j.1399-6576.1985.tb02225.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.